Literature DB >> 1565623

Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain.

J J Marchalonis1, H Kaymaz, F Dedeoglu, S F Schluter, D E Yocum, A B Edmundson.   

Abstract

We used mapping with synthetic overlapping peptides in combination with molecular modeling to analyze the IgG antibodies that humans naturally produce against human T-cell receptor beta chains and to localize the recognized peptide autoantigens in the three-dimensional structure of the molecule. Healthy individuals produce low levels of antibodies against T-cell receptor peptides, and these can be increased in autoimmune diseases. We characterized the reactivities in detail because IgG molecules reactive with self peptides occur in preparations of intravenous immunoglobulin and can be isolated by immunoaffinity chromatography. Natural IgG antibodies were directed against three major peptides. One corresponds to the first complementarity-determining region of the variable region. A second corresponds to the third framework of the variable region. The third is located in the constant region and is predicted to be a loop that extends out of the beta-barrel structure. This peptide is one that would give a characteristic structural distinction between the beta-chain constant region and the constant regions of immunoglobulin light chains to which beta chains are homologous. The capacity to bind these peptides is found in small fractions of normal polyclonal IgG, which contains both kappa chains and lambda chains. The activity is antibody-like in being confined to the Fab fragment and in its capacity to discriminate among homologous synthetic peptides corresponding to distinct beta-chain variable-region genes. We propose that a recognition and regulatory process naturally occurs that parallels the immune network for the regulation of the production of antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1565623      PMCID: PMC48859          DOI: 10.1073/pnas.89.8.3325

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Identification of the region of T cell receptor beta chain that interacts with the self-superantigen MIs-1a.

Authors:  A M Pullen; T Wade; P Marrack; J W Kappler
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

2.  Three-dimensional structure of a light chain dimer crystallized in water. Conformational flexibility of a molecule in two crystal forms.

Authors:  K R Ely; J N Herron; M Harker; A B Edmundson
Journal:  J Mol Biol       Date:  1989-12-05       Impact factor: 5.469

Review 3.  Structural correlates of a regulatory idiotope.

Authors:  C Victor-Kobrin; F A Bonilla; Z Barak; C Bona
Journal:  Immunol Rev       Date:  1989-08       Impact factor: 12.988

4.  Unusual features of the T-cell receptor C domains are revealed by structural comparisons with other members of the immunoglobulin superfamily.

Authors:  D Beale; J Coadwell
Journal:  Comp Biochem Physiol B       Date:  1986

5.  A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures. Determination of the full antigenic profile of the alpha-chain of human haemoglobin.

Authors:  A L Kazim; M Z Atassi
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

6.  Progressive sequence alignment as a prerequisite to correct phylogenetic trees.

Authors:  D F Feng; R F Doolittle
Journal:  J Mol Evol       Date:  1987       Impact factor: 2.395

7.  Localization of senescent cell antigen on band 3.

Authors:  M M Kay
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

8.  Natural mouse and human antibodies bind to a peptide derived from a germline VH chain. Evidence for evolutionary conserved self-binding locus.

Authors:  S V Kaveri; C Y Kang; H Köhler
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

9.  Antigen- and receptor-driven regulatory mechanisms. IV. Idiotype-bearing I-J+ suppressor T cell factors induce second-order suppressor T cells which express anti-idiotypic receptors.

Authors:  M S Sy; M H Dietz; R N Germain; B Benacerraf; M I Greene
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains.

Authors:  Y Yanagi; Y Yoshikai; K Leggett; S P Clark; I Aleksander; T W Mak
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

View more
  34 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function.

Authors:  B Liang; S Ardestani; J J Marchalonis; R R Watson
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 3.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 5.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 6.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

7.  Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

Authors:  Parvathi Ranganathan; Hao Chen; Miranda K Adelman; Samuel F Schluter
Journal:  J Neuroimmunol       Date:  2009-10-30       Impact factor: 3.478

8.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

Authors:  T Vassilev; C Gelin; S V Kaveri; M T Zilber; L Boumsell; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

9.  Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.

Authors:  Florence Jambou; Wei Zhang; Monique Menestrier; Isabelle Klingel-Schmitt; Olivier Michel; Sophie Caillat-Zucman; Abderrahim Aissaoui; Ludovic Landemarre; Sonia Berrih-Aknin; Sylvia Cohen-Kaminsky
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

10.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.